EP
IPSC icon

Essential Partners’s Century Therapeutics IPSC Stock Holding History

Essential Partners’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-119
Closed -$66 – 2729
2025
Q2 		$66 Buy
+119
New +$64 ﹤0.01% 2120

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's IPSC Position: Q3 2025 in Review

Essential Partners sold out of Century Therapeutics (IPSC) in Q3 2025, closing a stake of 119 shares — an estimated $66 sold.

Essential Partners first reported a position in IPSC in Q2 2025 and held it in 1 quarter. The position peaked at $66 in Q2 2025. 57 funds tracked by Wall St. Rank hold IPSC as of Q3 2025.

  • Essential Partners reported no remaining Century Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 119 Century Therapeutics shares in Q3 2025, an estimated $66.
  • Essential Partners first reported a position in Century Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Century Therapeutics position peaked at $66 in Q2 2025.
  • 57 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.